Abstract
Patients' experiences of NTM pulmonary disease highlight important and unmet needs for better pharmacological treatment and education of medical staff https://bit.ly/3mjrlwh.
Original language | English |
---|---|
Article number | 00807-2020 |
Journal | ERJ open research |
Volume | 7 |
Issue number | 1 |
DOIs |
|
Publication status | Published - Jan 2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: ERJ open research, Vol. 7, No. 1, 00807-2020, 01.2021.
Research output: Contribution to journal › Comment/Letter to the editor › Academic
TY - JOUR
T1 - What is important for people with nontuberculous mycobacterial disease? An embarc-elf patient survey
T2 - An EMBARC-ELF patient survey
AU - Shteinberg, Michal
AU - Boyd, Jeanette
AU - Aliberti, Stefano
AU - Polverino, Eva
AU - Harris, Bridget
AU - Berg, Tove
AU - Posthumus, Annette
AU - Ruddy, Thomas
AU - Goeminne, Pieter
AU - Lloyd, Ernie
AU - Alan, Timothy
AU - Altenburg, Josje
AU - Crossley, Barbara
AU - Blasi, Francesco
AU - Chalmers, James
N1 - Funding Information: Support statement: This study was supported by the European Respiratory Society EMBARC Clinical Research Collaboration. Funding information for this article has been deposited with the Crossref Funder Registry. Funding Information: Conflict of interest: M. Shteinberg reports grants, personal fees and nonfinancial support from GSK, grants and personal fees from Novartis, personal fees from Boehringer Ingelheim, AstraZeneca, Kamada, Vertex Pharmaceuticals and Teva, nonfinancial support from Actelion, grants, personal fees and nonfinancial support from GSK, grants from Novartis, nonfinancial support from Rafa, and grants from Trudell Pharma, outside the submitted work. Jeanette Boyd is an employee of the European Lung Foundation. S. Aliberti reports advisory fees and research support from Bayer Healthcare; speaker fees from Grifols; advisory fees from Astra Zeneca; advisory and speaker fees from Zambon; advisory and speaker fees, and research support from Chiesi and Insmed; advisory and speaker fees from GlaxoSmithKline; speaker fees from Menarini; advisory fees from ZetaCube Srl; and research support from Fisher & Paykel, all outside the submitted work. E. Polverino has nothing to disclose. B. Harris has nothing to disclose. T. Berg has nothing to disclose. A. Posthumus has nothing to disclose. T. Ruddy has nothing to disclose. P. Goeminne has nothing to disclose. E. Lloyd has nothing to disclose. T. Alan has nothing to disclose. J. Altenburg has nothing to disclose. B. Crossley has nothing to disclose. F. Blasi reports a research grant and an advisory fee from AstraZeneca; a research grant from Bayer; research grants and advisory fees from Chiesi and GSK; advisory fees from Grifols, Guidotti Funding Information: and Insmed; a research grant and an advisory fee from Menarini; an advisory fee from Novartis; a research grant and an advisory fee from Pfizer; and advisory fees from Zambon and Vertex, all outside the submitted work. J. Chalmers reports grants and personal fees from AstraZeneca and Boehringer Ingelheim, personal fees from Chiesi, grants and personal fees from GlaxoSmithKline, grants from Gilead Sciences, grants and personal fees from Insmed, and personal fees from Novartis and Zambon, outside the submitted work.
PY - 2021/1
Y1 - 2021/1
N2 - Patients' experiences of NTM pulmonary disease highlight important and unmet needs for better pharmacological treatment and education of medical staff https://bit.ly/3mjrlwh.
AB - Patients' experiences of NTM pulmonary disease highlight important and unmet needs for better pharmacological treatment and education of medical staff https://bit.ly/3mjrlwh.
UR - http://www.scopus.com/inward/record.url?scp=85115695322&partnerID=8YFLogxK
U2 - https://doi.org/10.1183/23120541.00807-2020
DO - https://doi.org/10.1183/23120541.00807-2020
M3 - Comment/Letter to the editor
C2 - 33614773
SN - 2312-0541
VL - 7
JO - ERJ open research
JF - ERJ open research
IS - 1
M1 - 00807-2020
ER -